Profile data is unavailable for this security.
About the company
Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.
- Revenue in GBP (TTM)0.00
- Net income in GBP-4.26m
- Incorporated2004
- Employees5.00
- LocationSareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
- Phone+44 122 349 7700
- Fax+44 122 349 7701
- Websitehttps://sareum.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Provexis plc | 598.08k | -496.59k | 14.14m | 2.00 | -- | 14.10 | -- | 23.65 | -0.0002 | -0.0002 | 0.0003 | 0.0004 | 0.6717 | 3.04 | 2.95 | 299,040.00 | -55.78 | -48.82 | -41.86 | -33.68 | 46.72 | 86.14 | -83.03 | -97.64 | 1.96 | -- | 0.00 | -- | -8.51 | 10.58 | -71.79 | -- | -- | -- |
| Genincode PLC | 1.72m | -6.73m | 15.48m | 28.00 | -- | 1.76 | -- | 9.02 | -0.0703 | -0.0703 | 0.0179 | 0.0497 | 0.168 | 16.36 | 2.88 | 61,285.71 | -65.92 | -- | -72.37 | -- | 47.55 | -- | -392.31 | -- | 5.85 | -- | 0.0632 | -- | 23.92 | -- | -34.21 | -- | -- | -- |
| Chill Brands Group PLC | 146.62k | -3.64m | 15.95m | 2.00 | -- | -- | -- | 108.77 | -0.0142 | -0.0142 | 0.0006 | -0.0024 | 0.0319 | 0.0992 | 0.3639 | 73,310.00 | -79.21 | -72.55 | -141.46 | -105.35 | 53.05 | -- | -2,485.30 | -1,625.46 | 0.6499 | -8.48 | 1.17 | -- | -86.73 | -50.89 | 23.50 | -- | -35.95 | -- |
| OptiBiotix Health PLC | 689.10k | -13.17m | 17.63m | 3.00 | -- | 1.75 | -- | 25.58 | -0.1489 | -0.1489 | 0.0078 | 0.1029 | 0.0426 | 2.28 | 1.25 | 229,700.00 | -81.35 | 17.83 | -83.43 | 18.66 | 49.31 | 54.87 | -1,911.88 | 190.54 | 3.24 | -0.089 | 0.00 | -- | -79.35 | 19.05 | -58.68 | 6.28 | 30.03 | -- |
| Destiny Pharma PLC | 0.00 | -5.97m | 18.35m | 20.00 | -- | 1.54 | -- | -- | -0.0759 | -0.0759 | 0.00 | 0.1251 | 0.00 | -- | -- | 0.00 | -48.68 | -47.98 | -52.87 | -52.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.80 | -- | -45.97 | -- |
| LungLife AI Inc | 36.99k | -4.35m | 18.72m | 19.00 | -- | 1.24 | -- | 506.00 | -0.1708 | -0.1708 | 0.0015 | 0.2497 | 0.0038 | -- | 0.1474 | 1,946.96 | -44.11 | -- | -50.09 | -- | 100.00 | -- | -11,767.39 | -- | -- | -- | 0.0419 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Verici DX PLC | 15.28k | -9.02m | 19.42m | 14.00 | -- | 2.54 | -- | 1,271.02 | -0.0529 | -0.0529 | 0.00009 | 0.0316 | 0.0013 | -- | 0.1152 | 1,018.63 | -77.76 | -- | -92.28 | -- | 84.21 | -- | -59,015.79 | -- | -- | -- | 0.0232 | -- | -- | -- | -36.94 | -- | -- | -- |
| Skinbiotherapeutics PLC | 161.65k | -2.88m | 19.54m | 11.00 | -- | 5.08 | -- | 120.86 | -0.0165 | -0.0165 | 0.0009 | 0.0192 | 0.0522 | 0.8871 | 0.4181 | 14,695.45 | -93.07 | -52.07 | -115.26 | -57.33 | 62.90 | -- | -1,784.70 | -4,694.37 | 6.48 | -379.78 | 0.0259 | -- | 76.65 | -- | -1.52 | -- | 18.00 | -- |
| C4X Discovery Holdings PLC | 24.68m | 10.57m | 21.57m | 49.00 | 2.04 | 0.8765 | 1.97 | 0.8738 | 0.0419 | 0.0419 | 0.0979 | 0.0976 | 1.18 | -- | 5.02 | 503,673.50 | 50.37 | -66.17 | 55.00 | -76.79 | 99.94 | 97.43 | 42.81 | -416.04 | -- | -- | 0.0104 | -- | -36.64 | -24.70 | -36.16 | -- | -16.37 | -- |
| Oncimmune Holdings PLC | 1.15m | -6.15m | 21.58m | 56.00 | -- | 32.84 | -- | 18.73 | -0.0859 | 0.0507 | 0.0159 | 0.0089 | 0.1239 | 1.08 | 0.5941 | -- | -66.15 | -- | -131.46 | -- | 68.75 | -- | -533.94 | -- | 3.75 | -1.96 | 0.8897 | -- | -- | -- | -- | -- | -- | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -7.17m | 22.42m | 14.00 | -- | 5.21 | -- | -- | -0.007 | -0.007 | 0.00 | 0.0032 | 0.00 | -- | -- | 0.00 | -95.17 | -73.59 | -107.02 | -86.78 | -- | -- | -- | -- | -- | -71.62 | 0.4735 | -- | -- | -- | 21.96 | -- | 46.18 | -- |
| Sareum Holdings Plc | 0.00 | -4.26m | 27.17m | 5.00 | -- | 45.07 | -- | -- | -0.0614 | -0.0614 | 0.00 | 0.0059 | 0.00 | -- | -- | 0.00 | -160.20 | -71.41 | -195.05 | -81.48 | -- | -- | -- | -19,709.24 | -- | -6.61 | 0.00 | -- | -- | -- | -46.96 | -- | -- | -- |
| Science in Sport PLC | 65.93m | -7.07m | 28.71m | 158.00 | -- | 0.7213 | -- | 0.4354 | -0.0464 | -0.0464 | 0.4239 | 0.2184 | 0.8479 | 4.20 | 3.83 | 417,278.50 | -9.09 | -9.69 | -13.75 | -11.97 | 41.88 | 47.09 | -10.72 | -11.94 | 0.6921 | -2.31 | 0.2825 | -- | 1.97 | 32.50 | -96.47 | -- | 49.81 | -- |
| Oxford Biodynamics PLC | 510.00k | -10.83m | 28.97m | 45.00 | -- | 3.10 | -- | 56.81 | -0.0729 | -0.0729 | 0.0035 | 0.0299 | 0.0371 | 0.7987 | 0.332 | 11,333.33 | -78.82 | -39.72 | -105.32 | -45.52 | 52.16 | -- | -2,122.75 | -1,324.62 | 1.72 | -7.50 | 0.5154 | -- | 231.17 | -15.53 | -61.34 | -- | -1.60 | -- |
| CRUSHMETRIC Group Ltd | 400.23k | -883.64k | 30.07m | 20.00 | -- | 1.17 | -- | 75.13 | -0.0072 | -0.0072 | 0.0028 | 0.1067 | 0.0255 | 7.14 | 2.64 | 20,011.57 | -5.72 | -40.65 | -8.35 | -- | 34.66 | 37.39 | -224.56 | -140.54 | 0.072 | -14.42 | 0.0558 | -- | 119.19 | -1.40 | -7.26 | -- | 12.11 | -- |
| Arecor Therapeutics PLC | 3.38m | -9.42m | 39.36m | 51.00 | -- | 2.98 | -- | 11.65 | -0.3108 | -0.3108 | 0.1114 | 0.4314 | 0.1805 | -- | 0.7516 | 66,254.90 | -50.32 | -- | -66.40 | -- | -- | -- | -278.81 | -- | 2.28 | -- | 0.0125 | -- | 107.51 | -- | -50.11 | -- | -- | -- |
Data as of Apr 19 2024. Currency figures normalised to Sareum Holdings PLC's reporting currency: UK Pound GBX
14.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Hargreaves Lansdown Asset Management Ltd.as of 02 Jan 2024 | 4.49m | 6.26% |
| HSBC Global Asset Management (UK) Ltd.as of 02 Jan 2024 | 3.16m | 4.40% |
| Jarvis Investment Management Ltd.as of 02 Jan 2024 | 1.41m | 1.96% |
| IG Markets Ltd.as of 02 Jan 2024 | 423.00k | 0.59% |
| Rowan Dartington & Co. Ltd. (Broker)as of 02 Jan 2024 | 171.00k | 0.24% |
| HSBC Bank Plc (Market-Maker)as of 02 Jan 2024 | 108.00k | 0.15% |
| J. M. Finn & Co. Ltd.as of 02 Jan 2024 | 94.00k | 0.13% |
| iDealing.com Ltd.as of 02 Jan 2024 | 91.00k | 0.13% |
| Evelyn Partners Investment Management Services Ltd.as of 02 Jan 2024 | 91.00k | 0.13% |
| Eurizon Capital SGR SpAas of 02 Jan 2024 | 86.00k | 0.12% |
More ▼
Data from 31 Dec 2023 - 02 Apr 2024Source: FactSet Research Systems Inc.
